PHARMAC responds on TNF inhibitors for inflammatory arthritis.
作者信息
Metcalfe Scott, Moodie Peter, Grocott Rachel, Wilkinson Tommy
出版信息
N Z Med J. 2005 Dec 16;118(1227):U1799.
PMID:16372039
Abstract
摘要
相似文献
1
PHARMAC responds on TNF inhibitors for inflammatory arthritis.
N Z Med J. 2005 Dec 16;118(1227):U1799.
2
TNF inhibitors for inflammatory arthritis in New Zealand.
N Z Med J. 2005 Oct 28;118(1224):U1706.
3
[Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
Pharm Unserer Zeit. 2003;32(5):420-5. doi: 10.1002/pauz.200300042.
4
Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
N Z Med J. 2005 Oct 7;118(1223):U1690.
5
Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
Med J Aust. 2004 Oct 18;181(8):457; discussion 457-8.
6
[Solutions for off-label therapy].
Z Rheumatol. 2003;62(Suppl 2):II54-6. doi: 10.1007/s00393-003-1216-1.
7
NICE and new drugs for rheumatoid arthritis.
Lancet. 2008 May 3;371(9623):1477. doi: 10.1016/S0140-6736(08)60629-7.
8
Comment on: Modelling the cost effectiveness of TNF antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
Rheumatology (Oxford). 2008 Jul;47(7):1106-7; author reply 1107. doi: 10.1093/rheumatology/ken105. Epub 2008 Mar 7.
9
PHARMAC responds on long-acting insulin analogues.
N Z Med J. 2005 Oct 28;118(1224):U1716.
10
Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!
Ann Rheum Dis. 2005 Nov;64(11):1529-31. doi: 10.1136/ard.2005.045351. Epub 2005 Aug 26.
Zotero 插件